Viewing Study NCT06483906


Ignite Creation Date: 2025-12-26 @ 11:00 AM
Ignite Modification Date: 2026-01-01 @ 5:12 AM
Study NCT ID: NCT06483906
Status: RECRUITING
Last Update Posted: 2024-07-22
First Post: 2024-06-26
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML.
Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module